<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p35" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_35{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_35{left:341px;bottom:30px;}
#t3_35{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_35{left:377px;bottom:30px;}
#t5_35{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_35{left:540px;bottom:30px;}
#t7_35{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_35{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_35{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_35{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_35{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_35{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_35{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_35{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_35{left:1108px;bottom:28px;letter-spacing:0.29px;}
#tg_35{left:36px;bottom:182px;}
#th_35{left:42px;bottom:176px;letter-spacing:0.12px;word-spacing:0.01px;}
#ti_35{left:759px;bottom:176px;letter-spacing:0.13px;}
#tj_35{left:833px;bottom:176px;letter-spacing:0.08px;}
#tk_35{left:36px;bottom:165px;}
#tl_35{left:42px;bottom:159px;letter-spacing:0.13px;word-spacing:-0.06px;}
#tm_35{left:327px;bottom:159px;}
#tn_35{left:36px;bottom:148px;}
#to_35{left:46px;bottom:142px;letter-spacing:0.14px;word-spacing:-0.06px;}
#tp_35{left:440px;bottom:142px;}
#tq_35{left:36px;bottom:131px;}
#tr_35{left:42px;bottom:125px;letter-spacing:0.1px;word-spacing:0.02px;}
#ts_35{left:36px;bottom:114px;}
#tt_35{left:50px;bottom:108px;letter-spacing:0.12px;}
#tu_35{left:81px;bottom:108px;letter-spacing:0.12px;}
#tv_35{left:159px;bottom:108px;letter-spacing:0.08px;word-spacing:0.05px;}
#tw_35{left:36px;bottom:778px;letter-spacing:0.48px;}
#tx_35{left:36px;bottom:760px;letter-spacing:0.25px;}
#ty_35{left:245px;bottom:778px;letter-spacing:0.32px;word-spacing:-0.31px;}
#tz_35{left:563px;bottom:786px;}
#t10_35{left:899px;bottom:778px;letter-spacing:0.34px;}
#t11_35{left:37px;bottom:656px;letter-spacing:-0.09px;}
#t12_35{left:38px;bottom:573px;letter-spacing:-0.09px;}
#t13_35{left:35px;bottom:475px;letter-spacing:-0.09px;}
#t14_35{left:35px;bottom:457px;letter-spacing:-0.09px;}
#t15_35{left:35px;bottom:439px;letter-spacing:-0.1px;}
#t16_35{left:35px;bottom:420px;letter-spacing:-0.11px;}
#t17_35{left:37px;bottom:322px;letter-spacing:-0.1px;}
#t18_35{left:37px;bottom:304px;letter-spacing:-0.1px;}
#t19_35{left:37px;bottom:285px;letter-spacing:-0.27px;word-spacing:0.17px;}
#t1a_35{left:247px;bottom:676px;letter-spacing:-0.09px;}
#t1b_35{left:247px;bottom:658px;letter-spacing:-0.1px;}
#t1c_35{left:247px;bottom:640px;letter-spacing:-0.09px;}
#t1d_35{left:336px;bottom:647px;}
#t1e_35{left:345px;bottom:640px;letter-spacing:-0.1px;}
#t1f_35{left:244px;bottom:573px;letter-spacing:-0.1px;}
#t1g_35{left:347px;bottom:581px;}
#t1h_35{left:355px;bottom:573px;letter-spacing:-0.1px;}
#t1i_35{left:599px;bottom:581px;}
#t1j_35{left:611px;bottom:573px;letter-spacing:-0.09px;}
#t1k_35{left:767px;bottom:581px;}
#t1l_35{left:244px;bottom:364px;letter-spacing:-0.08px;}
#t1m_35{left:244px;bottom:346px;letter-spacing:-0.1px;}
#t1n_35{left:244px;bottom:327px;letter-spacing:-0.1px;}
#t1o_35{left:439px;bottom:335px;letter-spacing:-0.11px;}
#t1p_35{left:467px;bottom:327px;letter-spacing:-0.1px;}
#t1q_35{left:728px;bottom:335px;letter-spacing:-0.07px;}
#t1r_35{left:244px;bottom:309px;letter-spacing:-0.09px;}
#t1s_35{left:244px;bottom:291px;letter-spacing:-0.1px;}
#t1t_35{left:244px;bottom:272px;letter-spacing:-0.1px;word-spacing:-0.08px;}
#t1u_35{left:504px;bottom:280px;letter-spacing:-0.09px;}
#t1v_35{left:524px;bottom:272px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t1w_35{left:809px;bottom:280px;}
#t1x_35{left:244px;bottom:254px;letter-spacing:-0.1px;}
#t1y_35{left:244px;bottom:236px;letter-spacing:-0.1px;}
#t1z_35{left:504px;bottom:241px;letter-spacing:-0.09px;}
#t20_35{left:524px;bottom:236px;letter-spacing:-0.1px;}
#t21_35{left:247px;bottom:499px;letter-spacing:-0.1px;}
#t22_35{left:247px;bottom:482px;letter-spacing:-0.1px;}
#t23_35{left:335px;bottom:490px;letter-spacing:-0.09px;}
#t24_35{left:247px;bottom:464px;letter-spacing:-0.09px;}
#t25_35{left:258px;bottom:446px;letter-spacing:-0.09px;}
#t26_35{left:258px;bottom:427px;letter-spacing:-0.11px;}
#t27_35{left:373px;bottom:435px;}
#t28_35{left:385px;bottom:427px;letter-spacing:-0.04px;}
#t29_35{left:258px;bottom:409px;letter-spacing:-0.09px;}
#t2a_35{left:399px;bottom:416px;}
#t2b_35{left:1071px;bottom:513px;letter-spacing:-0.09px;}
#t2c_35{left:1071px;bottom:494px;letter-spacing:-0.08px;}
#t2d_35{left:1071px;bottom:476px;letter-spacing:-0.1px;}
#t2e_35{left:1071px;bottom:458px;letter-spacing:-0.25px;}
#t2f_35{left:888px;bottom:515px;letter-spacing:-0.09px;}
#t2g_35{left:888px;bottom:497px;letter-spacing:-0.1px;}
#t2h_35{left:888px;bottom:478px;letter-spacing:-0.09px;}
#t2i_35{left:888px;bottom:460px;letter-spacing:-0.09px;}
#t2j_35{left:888px;bottom:442px;letter-spacing:-0.09px;}
#t2k_35{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_35{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_35{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_35{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_35{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_35{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_35{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_35{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_35{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s8_35{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s9_35{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_35{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sb_35{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sc_35{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts35" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg35Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg35" style="-webkit-user-select: none;"><object width="1210" height="935" data="35/35.svg" type="image/svg+xml" id="pdf35" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_35" class="t s0_35">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_35" class="t s1_35">® </span>
<span id="t3_35" class="t s0_35">(NCCN </span>
<span id="t4_35" class="t s1_35">® </span>
<span id="t5_35" class="t s0_35">), All rights reserved. NCCN Guidelines </span>
<span id="t6_35" class="t s1_35">® </span>
<span id="t7_35" class="t s0_35">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_35" class="t s2_35">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_35" class="t s2_35">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_35" class="t s3_35">NCCN Guidelines Version 4.2024 </span>
<span id="tb_35" class="t s3_35">Cancer of the Nasopharynx </span>
<span id="tc_35" class="t s4_35">NCCN Guidelines Index </span>
<span id="td_35" class="t s4_35">Table of Contents </span>
<span id="te_35" class="t s4_35">Discussion </span>
<span id="tf_35" class="t s5_35">NASO-2 </span>
<span id="tg_35" class="t s6_35">i </span>
<span id="th_35" class="t s7_35">The recommendations are based on clinical trial data for those with EBV-associated nasopharynx cancer (</span><span id="ti_35" class="t s8_35">Discussion</span><span id="tj_35" class="t s7_35">). </span>
<span id="tk_35" class="t s6_35">j </span>
<span id="tl_35" class="t s8_35">Principles of Radiation Therapy (NASO-A)</span><span id="tm_35" class="t s7_35">. </span>
<span id="tn_35" class="t s6_35">k </span>
<span id="to_35" class="t s8_35">Systemic Therapy for Nasopharyngeal Cancers (NASO-B)</span><span id="tp_35" class="t s7_35">. </span>
<span id="tq_35" class="t s6_35">l </span>
<span id="tr_35" class="t s7_35">High-risk features include bulky tumor volume, high serum EBV DNA copy number. </span>
<span id="ts_35" class="t s6_35">m </span>
<span id="tt_35" class="t s7_35">See </span><span id="tu_35" class="t s8_35">Discussion </span><span id="tv_35" class="t s7_35">on induction chemotherapy. </span>
<span id="tw_35" class="t s5_35">CLINICAL </span>
<span id="tx_35" class="t s5_35">STAGING </span>
<span id="ty_35" class="t s5_35">TREATMENT OF PRIMARY AND NECK </span>
<span id="tz_35" class="t s9_35">i </span>
<span id="t10_35" class="t s5_35">FOLLOW-UP </span>
<span id="t11_35" class="t s5_35">T1,N0,M0 </span>
<span id="t12_35" class="t s5_35">T2,N0,M0 </span>
<span id="t13_35" class="t s5_35">T0 (EBV+) </span>
<span id="t14_35" class="t s5_35">–2,N1,M0 </span>
<span id="t15_35" class="t s5_35">or </span>
<span id="t16_35" class="t s5_35">T3,N0,M0 </span>
<span id="t17_35" class="t s5_35">T3–4,N1–3,M0 </span>
<span id="t18_35" class="t s5_35">or </span>
<span id="t19_35" class="t s5_35">Any T,N2–3,M0 </span>
<span id="t1a_35" class="t sa_35" data-mappings='[[2,"fi"]]'>Deﬁnitive RT to </span>
<span id="t1b_35" class="t s5_35">nasopharynx and </span>
<span id="t1c_35" class="t s5_35">elective RT </span>
<span id="t1d_35" class="t s9_35">j </span>
<span id="t1e_35" class="t s5_35">to neck </span>
<span id="t1f_35" class="t sa_35" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t1g_35" class="t s9_35">j </span>
<span id="t1h_35" class="t s5_35">± concurrent systemic therapy </span>
<span id="t1i_35" class="t s9_35">k </span>
<span id="t1j_35" class="t s5_35">if high-risk features </span>
<span id="t1k_35" class="t s9_35">l </span>
<span id="t1l_35" class="t s5_35">Clinical trials (preferred) </span>
<span id="t1m_35" class="t s5_35">or </span>
<span id="t1n_35" class="t s5_35">Induction chemotherapy </span>
<span id="t1o_35" class="t s9_35">k,m </span>
<span id="t1p_35" class="t s5_35">followed by systemic therapy/RT </span>
<span id="t1q_35" class="t s9_35">j,k </span>
<span id="t1r_35" class="t s5_35">(preferred) (category 1) </span>
<span id="t1s_35" class="t s5_35">or </span>
<span id="t1t_35" class="t s5_35">Concurrent systemic therapy/RT </span>
<span id="t1u_35" class="t s9_35">j,k </span>
<span id="t1v_35" class="t s5_35">followed by adjuvant chemotherapy </span>
<span id="t1w_35" class="t s9_35">k </span>
<span id="t1x_35" class="t s5_35">or </span>
<span id="t1y_35" class="t s5_35">Concurrent systemic therapy/RT </span>
<span id="t1z_35" class="t s9_35">j,k </span>
<span id="t20_35" class="t s5_35">(category 2B) </span>
<span id="t21_35" class="t s5_35">Concurrent systemic </span>
<span id="t22_35" class="t s5_35">therapy/RT </span>
<span id="t23_35" class="t s9_35">j,k </span>
<span id="t24_35" class="t s5_35">• Consider induction </span>
<span id="t25_35" class="t s5_35">or adjuvant </span>
<span id="t26_35" class="t s5_35">chemotherapy </span>
<span id="t27_35" class="t s9_35">k </span>
<span id="t28_35" class="t s5_35">if </span>
<span id="t29_35" class="t s5_35">high-risk features </span>
<span id="t2a_35" class="t s9_35">l </span>
<span id="t2b_35" class="t s5_35">Recurrent or </span>
<span id="t2c_35" class="t s5_35">persistent </span>
<span id="t2d_35" class="t s5_35">disease </span>
<span id="t2e_35" class="t sb_35">(ADV-3) </span>
<span id="t2f_35" class="t sb_35">Post Systemic </span>
<span id="t2g_35" class="t sb_35">Therapy/RT </span>
<span id="t2h_35" class="t sb_35">or RT Neck </span>
<span id="t2i_35" class="t sb_35">Evaluation </span>
<span id="t2j_35" class="t sb_35">(FOLL-A, 2 of 2) </span>
<span id="t2k_35" class="t sc_35">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
